ClinicalTrials.Veeva

Menu

A Systematic Study of Retinal Structure and Function in Diabetic Macular Oedema

Q

Queen's University Belfast

Status

Completed

Conditions

Diabetic Macular Edema
Diabetes Mellitus
Diabetic Retinopathy

Study type

Observational

Funder types

Other

Identifiers

NCT02876393
14/NI/1025

Details and patient eligibility

About

Diabetic retinopathy(DR) is a sight threatening condition that occurs in persons with diabetes. DR arises as a consequence of damage to the retinal blood vessels and is related to the high and fluctuating sugar levels in the blood stream. An eye with DR will have abnormal appearing retinal blood vessels which become engorged and dilated, leaky and fragile or undergo closure. The net result is a picture of haemorrhage and or ischaemia (lack of blood supply). A particular feature of DR is the accumulation of fluid in the macula which is the central part of the retina and responsible for detailed eye sight. This peculiar form of DR is called Diabetic Macular Oedema (DMO). DMO can occur in isolation without other features of DR. DMO is commoner in type 2 diabetes where insulin resistance and abnormalities of blood fats are found. The investigators wish to study DR and DMO using high resolution retinal imaging and functional tests in normal participants, those participants with diabetes without any overt signs of disease and those with DR and DMO in order to understand how the condition develops and whether there are any unique risk factors that can be identified

Enrollment

172 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Group 1 (Healthy controls without DM):

  • Persons older than 18 years without DM
  • Fundus free of any signs of retinal disease
  • Best Corrected Visual Acuity of 20/40 (73 ETDRS letters) in both eyes

Group 2 (Persons with DM with no retinopathy):

  • Persons with Type 1 or type 2 diabetes older than 18 years
  • Normal fundus, Absence of features of DR or DMO in both eyes
  • Best Corrected Visual Acuity 20/40 (73 ETDRS letters) in at least one eye

Group 3:

  • Persons with Type 1 or type 2 diabetes 18 years and older
  • Fundus signs of mild, moderate or severe DR and or DMO
  • Best Corrected Visual Acuity 20/200 (33 ETDRS letters) or better

Exclusion criteria

  • Recent ocular surgical procedures performed within the previous 3 months
  • Presence of ocular confounding disorders such as neovascular age related macular degeneration, glaucoma or active uveitis
  • Serious life threatening conditions that would preclude attendance in the longitudinal part of the study
  • Neurological conditions that can impair vision

Trial design

172 participants in 2 patient groups

Cases
Description:
Persons with type 1 or type 2 DM with features of DR and or DMO ranging from extremely mild to severe.
Control definition
Description:
Persons with a history of type 1 or type 2 DM without any clinical features of DR or DMO in either eye or persons without a history of DM and without retinal disease in either eye.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems